ecrin-mdr-crcClinical2014Carcinoma, Squamous CellMetastatic Colorectal CancerSquamous Cell Carcinoma of Head and NeckHead and neck squamous cell carcinoma.Colorectal cancer.Squamous Cell Carcinoma of Head and Neck (SCCHN)Colorectal NeoplasmsCarcinoma escamoso de cabeza y cuello.Cáncer colorrectal metastásico.CancerCarcinoma, Squamous CellHead And Neck Squamous Cell Carcinoma.colorectal Cancer.Metastatic Colorectal CancerSquamous Cell Carcinoma Of Head And NeckCarcinoma Escamoso De Cabeza Y Cuello.cáncer Colorrectal Metastásico.Squamous Cell Carcinoma Of Head And Neck (scchn)Colorectal NeoplasmsCancerInterventionalhttps://newmdr.ecrin.org/Study/2171726CanadaNetherlandsBelgiumUnited StatesChinaItalyFranceGermanySpain7SCCHN,Resistance to cetuximab/panitumumabSquamous cell carcinomaRectal cancerParanasal sinusesINC280 200 mgLympth nodes of neckMucosal liningEpitheliumPharynxErbitux 5mg/mLINC280Parotid glandsC-MET inhibitorLarge intestineHead and neckLarynxColonCetuximabINC280 50 mgOral and nasal cavityECRIN MDRTerminatedfalseStudy of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab TherapyThis was an open-label, phase Ib, multicenter clinical trial to determine the MTD/RDE of the orally administered c-MET inhibitor INC280 in combination with cetuximab. This combination was to be explored in c-MET positive mCRC and HNSCC patients whose disease progressed on cetuximab or panitumumab treatment. The dose escalation part was to be guided by a Bayesian Logistic Regression Model with overdose control. At MTD/RDE, additional mCRC and HNSCC patients who progressed on cetuximab or panitumumab treatment were to be enrolled in two expansion groups to further assess the anti-tumor activity and the safety and tolerability of the combination of INC280 and cetuximab. Patients were to receive INC280 on a continuous bid dosing regimen and cetuximab every week. A treatment cycle was defined as 28 days with no scheduled break between cycles. The trial was terminated because of difficulties in identifying patients who met the eligibility criteria.2014-07-152171726NCT022053982014-000579-20